Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals

Hong Kong-listed mainland Chinese pharmaceutical companies, led by Innovent Biologics, are poised to deliver strong full-year profits as years of heavy research and development investment finally translate into commercial success. According to analysis from Macquarie Capital, despite ongoing domestic pricing pressures, earnings from innovative drugs are performing well in China. Innovent, notable for being the first Chinese firm cleared to sell a weight loss and diabetes drug, is a prime example, expecting to post a historic 984 million yuan ($143.5M) profit for 2025—a dramatic reversal from its 2024 loss. This milestone reflects a broader trend where surging drug sales and strategic out-licensing agreements with international partners are beginning to offset the initial capital-intensive phase of drug development.

Innovent's revenue surged approximately 45% in 2025 to roughly 11.9 billion yuan, a growth the company itself labeled a 'historic milestone.' This performance was bolstered by the launch of six new products last year. The company's journey, from its 2011 founding to a 2018 listing under Hong Kong's rules for pre-revenue biotech firms, exemplifies the sector's evolution. The projected profitability for Innovent and its peers indicates that China's biopharmaceutical industry is maturing beyond the pure R&D stage, moving into a sustainable phase driven by global market integration and commercial execution. This financial turnaround provides crucial validation for investors and could accelerate further innovation and international collaboration in the sector.